Aratana Therapeutics Inc. (NASDAQ:PETX) has been given a consensus rating of “Buy” by the nine brokerages that are covering the stock. Two equities research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $11.86.
Several equities research analysts have recently commented on the stock. Lake Street Capital reissued a “buy” rating and set a $15.00 target price on shares of Aratana Therapeutics in a research report on Tuesday, September 6th. Zacks Investment Research raised shares of Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.25 target price for the company in a research report on Wednesday, July 20th. Jefferies Group assumed coverage on shares of Aratana Therapeutics in a research report on Friday, August 19th. They set a “buy” rating and a $13.00 target price for the company. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a research report on Wednesday, August 17th. Finally, Barclays PLC decreased their target price on shares of Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th.
In other news, insider Peter Steven St sold 50,000 shares of the stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $9.25, for a total transaction of $462,500.00. Following the completion of the transaction, the insider now directly owns 642,793 shares of the company’s stock, valued at approximately $5,945,835.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Julia A. Stephanus sold 30,000 shares of the stock in a transaction that occurred on Tuesday, June 28th. The shares were sold at an average price of $6.25, for a total transaction of $187,500.00. Following the transaction, the insider now directly owns 127,503 shares of the company’s stock, valued at $796,893.75. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PETX. California State Teachers Retirement System increased its position in Aratana Therapeutics by 9.7% in the second quarter. California State Teachers Retirement System now owns 69,941 shares of the biopharmaceutical company’s stock worth $442,000 after buying an additional 6,211 shares in the last quarter. Bank of New York Mellon Corp increased its position in Aratana Therapeutics by 16.7% in the second quarter. Bank of New York Mellon Corp now owns 136,864 shares of the biopharmaceutical company’s stock worth $866,000 after buying an additional 19,590 shares in the last quarter. Tocqueville Asset Management L.P. bought a new position in Aratana Therapeutics during the second quarter worth $209,000. Iguana Healthcare Management LLC bought a new position in Aratana Therapeutics during the first quarter worth $1,070,000. Finally, Westend Capital Management LLC increased its position in Aratana Therapeutics by 37.2% in the first quarter. Westend Capital Management LLC now owns 123,190 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 33,410 shares in the last quarter. 85.56% of the stock is owned by hedge funds and other institutional investors.
Shares of Aratana Therapeutics (NASDAQ:PETX) opened at 9.28 on Monday. Aratana Therapeutics has a 12 month low of $2.56 and a 12 month high of $10.45. The firm has a 50 day moving average price of $9.13 and a 200-day moving average price of $6.98. The firm’s market cap is $328.65 million.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.37. Aratana Therapeutics had a negative net margin of 166.67% and a negative return on equity of 17.53%. The firm had revenue of $38.05 million for the quarter, compared to analyst estimates of $15.14 million. During the same quarter in the prior year, the business earned ($0.23) earnings per share. On average, analysts predict that Aratana Therapeutics will post ($0.77) EPS for the current fiscal year.
Aratana Therapeutics Company Profile
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.